Biden’s incoming Secretary of Health is a fan of ‘march in’ rights as a cost-containment tool for medicines. Two hold-overs from Trump Presidency may slow him down.
President Joe Biden’s nominee to run the US Department of Health & Human Services is reviving fears in industry about executive action to invoke so-called “march in” rights: seeking to suspend patent rights on medicines that rely in part on taxpayer funded research as a mechanism to control costs.
In his former role as Attorney General for the State of California, Xavier Becerra, joined in a letter seeking to...
Neither Kamala Harris nor Donald Trump mentioned drug pricing reforms in their presidential convention speeches.
The agency is clearly on the radar of former President Trump and his new coterie of tech moguls.
With the 4 July UK general election less than two weeks away, the Pink Sheet looks at the manifestos published by the major political parties and finds pledges to drive innovation, boost clinical trial activity and speed up regulatory procedures.
While more significant reforms are less likely under a second Biden term unless Democrats control both chambers of Congress, former President Trump could look to put his stamp on drug pricing reform by resurrecting one of his former policies involving international reference pricing and Medicare Part B drugs.
Congressional Budget Office responses to questions from US lawmakers on pharmacy benefit managers could add to the momentum for PBM reforms to go further than the current leading proposals.
Letter to US FDA by a bipartisan group of House members cites clinical trials sponsored by Eli Lilly and Pfizer as examples of a widespread industry practice. But any legislation to curtail such practices is not expected to be part of the BIOSECURE Act.
The agency is clearly on the radar of former President Trump and his new coterie of tech moguls.
